EC Number | Activating Compound | Comment | Organism | Structure |
---|---|---|---|---|
3.4.24.18 | additional information | contrary to meprin B only very little activation by trypsin treatment | Mus musculus | |
3.4.24.63 | Trypsin | activation, 5-20fold | Mus musculus | |
3.4.24.63 | Trypsin | only with larger substrates (azocasein or insulin B), not smaller substrates | Mus musculus | |
3.4.24.63 | Trypsin | by limited proteolysis (2 h at 37°C, with tosyl-Phe chloromethyl ketone treated trypsin, in 20 mM Tris-HCl buffer, pH 7.5) | Mus musculus |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
3.4.24.18 | 1,10-phenanthroline | - |
Mus musculus | |
3.4.24.18 | cysteine | - |
Mus musculus | |
3.4.24.18 | EDTA | - |
Mus musculus | |
3.4.24.18 | additional information | iodoacetate; L-trans-epoxysuccinyl-leucylamido-(4-guanidino)-butane (i.e. E-64); no inhibition by phosphoramidon; soybean trypsin inhibitor | Mus musculus | |
3.4.24.63 | 1,10-phenanthroline | strong | Mus musculus | |
3.4.24.63 | cysteine | - |
Mus musculus | |
3.4.24.63 | EDTA | strong | Mus musculus | |
3.4.24.63 | additional information | compound E-64; phosphoramidon, iodoacetic acid, 3,4-dichloroisocoumarin or soybean trypsin inhibitor | Mus musculus |
EC Number | Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|---|
3.4.24.18 | membrane | renal brush border membrane | Mus musculus | 16020 | - |
3.4.24.63 | membrane | renal brush-border membrane | Mus musculus | 16020 | - |
3.4.24.63 | additional information | cell surface endopeptidase | Mus musculus | - |
- |
EC Number | Metals/Ions | Comment | Organism | Structure |
---|---|---|---|---|
3.4.24.18 | Zinc | metalloendopeptidase | Mus musculus | |
3.4.24.63 | additional information | metalloendopeptidase according to inhibition profile | Mus musculus |
EC Number | Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
---|---|---|---|---|
3.4.24.18 | additional information | - |
amino acid composition (of meprin A and B) | Mus musculus |
3.4.24.18 | 90000 | - |
4 * 90000, mouse, SDS-PAGE, reducing conditions | Mus musculus |
3.4.24.63 | additional information | - |
amino acid composition and secondary structure similar to meprin A | Mus musculus |
3.4.24.63 | 90000 | - |
x * 90000, mouse, SDS-PAGE under reducing or non-reducing conditions | Mus musculus |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
3.4.24.18 | Mus musculus | - |
male ICR | - |
3.4.24.18 | Mus musculus male ICR | - |
male ICR | - |
3.4.24.63 | Mus musculus | - |
inbred strain C3H/He | - |
3.4.24.63 | Mus musculus | - |
male adults | - |
EC Number | Posttranslational Modification | Comment | Organism |
---|---|---|---|
3.4.24.18 | glycoprotein | complex-type glycosylation | Mus musculus |
3.4.24.63 | glycoprotein | - |
Mus musculus |
EC Number | Purification (Comment) | Organism |
---|---|---|
3.4.24.18 | - |
Mus musculus |
3.4.24.63 | papain-solubilized | Mus musculus |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
3.4.24.18 | kidney | - |
Mus musculus | - |
3.4.24.63 | kidney | brush border membrane | Mus musculus | - |
EC Number | Specific Activity Minimum [µmol/min/mg] | Specific Activity Maximum [µmol/min/mg] | Comment | Organism |
---|---|---|---|---|
3.4.24.18 | additional information | - |
4.6673 mg azocasein/min/mg (untreated enzyme), 7.2512 mg azocasein/min/mg (trypsin-treated enzyme) | Mus musculus |
3.4.24.18 | 0.095 | - |
Tyr-Leu-Val-Cys(SO3-)-Gly-Glu-Arg-Gly | Mus musculus |
3.4.24.18 | 1.38 | - |
oxidized insulin B-chain, trypsin-treated enzyme | Mus musculus |
3.4.24.18 | 4.54 | - |
n-bradykinin | Mus musculus |
3.4.24.63 | additional information | - |
0.4763 mg azocasein/min mg protein | Mus musculus |
3.4.24.63 | 0.367 | 0.467 | Tyr-Leu-Val-Cys(SO3-)-Gly-Glu-Arg-Gly as substrate | Mus musculus |
3.4.24.63 | 1.82 | - |
insulin B-chain as substrate | Mus musculus |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.4.24.18 | azocasein + H2O | - |
Mus musculus | fragments of azocasein | - |
? | |
3.4.24.18 | azocasein + H2O | - |
Mus musculus male ICR | fragments of azocasein | - |
? | |
3.4.24.18 | bradykinin + H2O | - |
Mus musculus | Arg-Pro-Pro-Gly + Phe-Ser-Pro-Phe-Arg | - |
? | |
3.4.24.18 | Insulin B-chain + H2O | prevalent cleavage sites are Gly20-Glu21, Phe24-Phe25 and Phe25-Tyr26 | Mus musculus | Hydrolyzed insulin B-chain | 15 different peptide fragments | ? | |
3.4.24.18 | Insulin B-chain + H2O | 10 cleavage sites | Mus musculus | Hydrolyzed insulin B-chain | 15 different peptide fragments | ? | |
3.4.24.18 | Insulin B-chain + H2O | oxidized form | Mus musculus | Hydrolyzed insulin B-chain | 15 different peptide fragments | ? | |
3.4.24.18 | Insulin B-chain + H2O | prevalent cleavage sites are Gly20-Glu21, Phe24-Phe25 and Phe25-Tyr26 | Mus musculus male ICR | Hydrolyzed insulin B-chain | 15 different peptide fragments | ? | |
3.4.24.18 | Insulin B-chain + H2O | 10 cleavage sites | Mus musculus male ICR | Hydrolyzed insulin B-chain | 15 different peptide fragments | ? | |
3.4.24.18 | Insulin B-chain + H2O | oxidized form | Mus musculus male ICR | Hydrolyzed insulin B-chain | 15 different peptide fragments | ? | |
3.4.24.18 | Tyr-Leu-Val-Cys(SO3-)-Gly-Glu-Arg-Gly + H2O | synthetic peptide derived from insulin B-chain | Mus musculus | ? | - |
? | |
3.4.24.18 | Tyr-Leu-Val-Cys(SO3-)-Gly-Glu-Arg-Gly + H2O | synthetic peptide derived from insulin B-chain | Mus musculus male ICR | ? | - |
? | |
3.4.24.63 | azocasein + H2O | poor substrate | Mus musculus | ? | - |
? | |
3.4.24.63 | azocasein + H2O | mouse enzyme: poor substrate unless activated by trypsin treatment (i.e. latent azocaseinase activity) | Mus musculus | ? | - |
? | |
3.4.24.63 | Insulin B-chain + H2O | 4 cleavage sites (2 major and 2 minor): His5-Leu6, Leu6-Cys(SO3-)7, Ala14-Leu15, Cys(SO3-)19-Gly20 | Mus musculus | ? | - |
? | |
3.4.24.63 | Insulin B-chain + H2O | yielding at least 7 product peptides | Mus musculus | ? | - |
? | |
3.4.24.63 | additional information | no substrates are nitrobradykinin | Mus musculus | ? | - |
? | |
3.4.24.63 | Tyr-Leu-Val-Cys(SO3-)-Gly-Glu-Arg-Gly + H2O | synthetic octapeptide, derived from insulin B-chain | Mus musculus | ? | - |
? |
EC Number | Subunits | Comment | Organism |
---|---|---|---|
3.4.24.18 | tetramer | 4 * 90000, mouse, SDS-PAGE, reducing conditions | Mus musculus |
3.4.24.63 | oligomer | x * 90000, mouse, SDS-PAGE under reducing or non-reducing conditions | Mus musculus |
EC Number | Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|---|
3.4.24.18 | 37 | - |
assay at | Mus musculus |
3.4.24.63 | 37 | - |
assay at | Mus musculus |
EC Number | Temperature Stability Minimum [°C] | Temperature Stability Maximum [°C] | Comment | Organism |
---|---|---|---|---|
3.4.24.18 | 58 | - |
t1/2: 50 min | Mus musculus |
3.4.24.63 | 58 | - |
t1/2: 2.5 min, less stable than meprin A | Mus musculus |